Sugi Predict

Sugi Predict / Compounds / SCHEMBL22720076

SCHEMBL22720076

SCHEMBL22720076

COC(=O)C1(C(=O)N2CCOCC2)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.45
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ GLA P06280 1/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ HTT P42858 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ MGLL Q99685 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31733069 0.94 CYP3A4 (0.44) GAAALDH1A1CYP3A4CYP2C19GLA
SCHEMBL951610 0.83 PSEN1 (0.40) GAAALDH1A1SMN1; SMN2L3MBTL1NPSR1
SCHEMBL31085608 0.82 PSEN1 (0.40) GAAALDH1A1CYP3A4CYP2C19SMN1; SMN2
SCHEMBL22725318 0.81 MEN1 (0.40) GAAALDH1A1SMN1; SMN2HPGDL3MBTL1
SCHEMBL31733073 0.81 VNN1 (0.38) CYP3A4CYP2C19PKM
SCHEMBL31733041 0.81 HDAC2 (0.37) ALDH1A1CYP3A4CYP2C19TSHRHSD17B10
SCHEMBL22967561 0.80 HSD11B1 (0.43) USP2
SCHEMBL31733190 0.79 PLAT (0.33) GAAALDH1A1CYP3A4SMN1; SMN2
SCHEMBL22967508 0.79 HSD11B1 (0.42) —
SCHEMBL15106195 0.79 PSEN1 (0.43) ALDH1A1HPGDUSP2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109714-A1 PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF GENFLEET THERAPEUTICS SHANGHAI INC (CN) 2026-04-23 — — US disclosed
EP-4631948-A1 NOVEL TRICYCLIC COMPOUND AS KRAS G12D INHIBITOR, AND USE THEREOF SK Biopharmaceuticals Co., Ltd. (KR) 2025-10-15 — — EP disclosed
EP-4626888-A1 COMPOUNDS Redx Pharma Limited (GB) 2025-10-08 — — EP disclosed
EP-4592295-A1 PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2025-07-30 — — EP disclosed
US-20250186456-A1 PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2025-06-12 — — US disclosed
WO-2025059040-A1 MUTANT KRAS MODULATORS AND USES THEREOF NEWAVE PHARMACEUTICAL INC. (US) 2025-03-20 — — WO disclosed
CN-113874374-B Hydrogenated pyridopyrimidine derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2024-12-27 — — CN disclosed
US-20240246954-A1 COMPOSITIONS AND METHODS FOR INHIBITING KRAS THERAS, INC. 2024-07-25 — — US disclosed
EP-4397664-A1 PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2024-07-10 — — EP disclosed
WO-2024123102-A1 NOVEL TRICYCLIC COMPOUND AS KRAS G12D INHIBITOR, AND USE THEREOF 에스케이바이오팜 주식회사 2024-06-13 — — WO disclosed
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2023-11-09 — — US disclosed
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2023-11-09 — — US disclosed
WO-2023137223-A1 PAN-KRAS INHIBITORS AND USES THEREOF NEWAVE PHARMACEUTICAL INC. (US) 2023-07-20 — — WO disclosed
WO-2023030385-A1 PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF 劲方医药科技(上海)有限公司 2023-03-09 — — WO disclosed
WO-2022177917-A2 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS THERAS, INC. (US) 2022-08-25 — — WO disclosed
CN-113874374-A Hydrogenated pyridopyrimidine derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2021-12-31 — — CN disclosed
US-20210040089-A1 KRAS MUTANT PROTEIN INHIBITORS JACOBIO PHARMACEUTICALS CO., LTD. 2021-02-11 — — US disclosed
WO-2021023247-A1 KRAS MUTANT PROTEIN INHIBITOR JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2021-02-11 — — WO disclosed
WO-2020238791-A1 HYDROPYRIDOPYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 江苏恒瑞医药股份有限公司 2020-12-03 — — WO disclosed
WO-2020238791-A1 HYDROPYRIDOPYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 江苏恒瑞医药股份有限公司 2020-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246954-A1 COMPOSITIONS AND METHODS FOR INHIBITING KRAS KRAS, NRAS, HRAS GAA 655/4885ALDH1A1 2557/4885CYP3A4 2946/4885
US-20250186456-A1 PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF KRAS, NRAS, TP53 GAA 3169/4885ALDH1A1 3323/4885CYP3A4 2163/4885
US-20260109714-A1 PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF KRAS, NRAS, HRAS GAA 4554/4885ALDH1A1 1260/4885CYP3A4 1017/4885
US-20210040089-A1 KRAS MUTANT PROTEIN INHIBITORS KRAS, NRAS, APC GAA 2779/4885ALDH1A1 3926/4885CYP3A4 4268/4885
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF KRAS, NRAS, HRAS GAA 3036/4885ALDH1A1 1158/4885CYP3A4 1166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.